Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 181 clinical trials
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

which was an Immune Checkpoint Inhibitor (ICI).

measurable disease
carcinoma
nivolumab
advanced renal cell carcinoma
  • 0 views
  • 08 Jul, 2022
  • 30 locations
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03)  

with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI). The primary objective is to determine whether tusamitamab ravtansine improves the overall survival

  • 119 views
  • 18 Aug, 2022
  • 5 locations
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

with immune-checkpoint inhibitor drugs. Studying samples of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help doctors learn more about the effects of treatment on

genitourinary cancer
infliximab
cancer
microbiota
endoscopy
  • 0 views
  • 15 Jul, 2022
  • 1 location
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (IMAGINE)

This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment

  • 4 views
  • 03 May, 2022
  • 341 locations
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (DG-03)

clinical testing. T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor administered to HER2-positive gastric, GEJ and esophageal cancer patients who have not received prior

pembrolizumab
fluorouracil
adenocarcinoma
oxaliplatin
metastatic adenocarcinoma
  • 0 views
  • 08 Jul, 2022
  • 51 locations
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (EV-103)

This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used

hearing loss
pembrolizumab
glomerular filtration rate
invasive bladder cancer
enfortumab vedotin
  • 324 views
  • 21 Apr, 2022
  • 105 locations
A Study of VS-6766 and VS-6766 + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202)

This study will assess the safety and efficacy of VS-6766 monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.

lung carcinoma
measurable disease
recurrent non-small cell lung cancer
BRAF
KRAS
  • 1 views
  • 24 Jul, 2022
  • 40 locations
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.

  • 0 views
  • 12 Jul, 2022
  • 122 locations
Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC

Rationale: Immune checkpoint inhibitors have shown to improve the overall survival for patients with metastasized non-small cell lung carcinoma (NSCLC) but the optimal dosing and patient selection are still a matter of discussion. The pembrolizumab dose, for instance, may be reduced significantly without decreasing treatment efficacy. Furthermore, as approximately only …

pembrolizumab
carcinoma
cancer chemotherapy
lung carcinoma
  • 0 views
  • 25 Jul, 2021
  • 1 location
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Background More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year. Because these tumors are so rare, there are few proven therapies. This study will test whether the immunotherapy drug nivolumab is an effective …

karnofsky performance status
MRI
gliosarcoma
carcinoma
renal function
  • 120 views
  • 24 Jul, 2022
  • 11 locations